Literature DB >> 20643514

Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: report of the ASTRO Emerging Technology Committee.

Mark K Buyyounouski1, Peter Balter, Brett Lewis, David J D'Ambrosio, Thomas J Dilling, Robert C Miller, Tracey Schefter, Wolfgang Tomé, Eleanor E R Harris, Robert A Price, Andre A Konski, Paul E Wallner.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20643514     DOI： 10.1016/j.ijrobp.2010.04.010

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  12 in total

1.  Lobectomy: no port at all?

Authors:  Yanping Ren; Yuxin Jiao; Xiangpeng Zheng
Journal:  Ann Transl Med       Date:  2017-05

2.  Quality and safety in stereotactic radiosurgery and stereotactic body radiation therapy: can more be done?

Authors:  Timothy D Solberg; Paul M Medin
Journal:  J Radiosurg SBRT       Date:  2011

3.  Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT).

Authors:  S García-Cabezas; C Bueno; E Rivin; J M Roldán; A Palacios-Eito
Journal:  Clin Transl Oncol       Date:  2015-05-29       Impact factor: 3.405

4.  Clinically relevant biomarkers in targeted radiotherapy.

Authors:  Baldassarre Stea; John Gordon
Journal:  Clin Exp Metastasis       Date:  2012-08-11       Impact factor: 5.150

5.  Oligometastatic disease, the curative challenge in radiation oncology.

Authors:  Amalia Palacios-Eito; Sonia García-Cabezas
Journal:  World J Clin Oncol       Date:  2015-08-10

6.  Optimal set of grid size and angular increment for practical dose calculation using the dynamic conformal arc technique: a systematic evaluation of the dosimetric effects in lung stereotactic body radiation therapy.

Authors:  Ji-Yeon Park; Siyong Kim; Hae-Jin Park; Jeong-Woo Lee; Yeon-Sil Kim; Tae-Suk Suh
Journal:  Radiat Oncol       Date:  2014-01-04       Impact factor: 3.481

7.  Dosimetric comparison of three-dimensional conformal radiotherapy, intensity modulated radiotherapy, and helical tomotherapy for lung stereotactic body radiotherapy.

Authors:  Rajesh Ashok Kinhikar; Yogesh G Ghadi; Priyadarshini Sahoo; Sarbani Ghosh Laskar; Deepak D Deshpande; Shyam K Shrivastava; Jaiprakash Agarwal
Journal:  J Med Phys       Date:  2015 Oct-Dec

8.  Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer.

Authors:  Min-Jeong Kim; Seung-Gu Yeo; Eun Seok Kim; Chul Kee Min; Pyung Se An
Journal:  Oncol Lett       Date:  2012-12-18       Impact factor: 2.967

9.  Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis.

Authors:  Yuko Shirata; Keiichi Jingu; Masashi Koto; Masaki Kubozono; Ken Takeda; Toshiyuki Sugawara; Noriyuki Kadoya; Haruo Matsushita
Journal:  Radiat Oncol       Date:  2012-10-31       Impact factor: 3.481

10.  The impact of emphysema on dosimetric parameters for stereotactic body radiotherapy of the lung.

Authors:  Satoru Ochiai; Yoshihito Nomoto; Yasufumi Yamashita; Tomoki Inoue; Shuuichi Murashima; Daisuke Hasegawa; Yoshie Kurita; Yui Watanabe; Yutaka Toyomasu; Tomoko Kawamura; Akinori Takada; Shigeki Kobayashi; Hajime Sakuma
Journal:  J Radiat Res       Date:  2016-07-05       Impact factor: 2.724
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.